Blog Posts

Samer Al Hadidi: Prior Exposure to Belantamab Mafodotin with Idecabtagene Vicluecel in Multiple Myeloma

Samer Al Hadidi/LinkedIn

Mar 18, 2025, 10:01

Samer Al Hadidi: Prior Exposure to Belantamab Mafodotin with Idecabtagene Vicluecel in Multiple Myeloma

Samer Al Hadidi, Assistant professor at UAMS Myeloma Center, posted on LinkedIn about recent paper he and colleagues co-authored, titled “Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma” published on American Society of Hematology Blood Advances.

Authors: Bhavesh Mohan Lal, Marah Alzubi, Jawad Alrawabdeh, John D. Shaughnessy, Jr, Fenghuang Zhan, Eric R. Siegel, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Samer Al Hadidi

“Check out recent work published American Society of Hematology Blood Advances.

Prior Exposure to Belantamab, Mafodotin Influences Outcomes with Idecabtagene ,Vicluecel in Patients with Multiple Myeloma.”

American Society of Hematology Blood Advances Bhavesh Mohan Lal cancer Carolina Schinke Eric R. Siegel Fenghuang Zhan Frits Van Rhee Jawad Alrawabdeh John D. Shaughnessy Jr Marah Alzubi Maurizio Zangari multiple myeloma OncoDaily Oncology Samer Al Hadidi Sharmilan Thanendrarajan

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Writer?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen

Top 10 Immunotherapy Trials in Lung Cancer to Watch at ESMO 2025

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...